Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The Russian clinical trial context deserves specific mention
They've provided answers when I couldn't find any
10.1074/jbc.M009674200 93
Reasonable candidates include: Mild to moderate IBD as an adjunct (never as sole therapy, always with GI oversight) IBS with a documented inflammatory component Post-infectious gut dysfunction where both tissue damage and persistent low-grade inflammation are present Mixed presentations, heartburn plus intestinal sensitivity plus food reactivity, where the clinical picture suggests multiple mechanisms Where this falls apart is when people treat it as a silver bullet
For a more detailed research summary with study citations, see our complete BPC-157 research guide and our mechanisms of action article
US$ 27.33
US$ 24.52
US$ 22.98
